ExpantLab identified that patients with certain human leukocyte antigen genotypes that are related to immune function are more likely to develop an immune response to implants containing cobalt chrome, leading to pain and joint failure.
“Essentially, the immune system attacks the implant in a process similar to how a patient rejects an organ transplant,” David Langton, PhD, director of ExplantLab, told Genetic Engineering and Biotechnology News.
Scientists used these findings to develop Orthotype, a machine-learning algorithm that uses a patient’s genotype to find the probability of the patient having a negative reaction to cobalt chrome implants.
The algorithm can help surgeons select an implant based on the manufactured material most suited to the individual patient, lowering the likelihood for duplicate surgeries.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.